Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
都柏林，2025年1月3日（全球新聞資訊）—— Avadel Pharmaceuticals plc（納斯達克：AVDL），一家專注於轉變藥物以改善生活的生物製藥公司，今天宣佈將於2025年1月8日星期三東部時間下午4:30舉辦電話會議和現場直播，以提供公司更新並討論截至2024年12月31日的第四季度和全年初步未經審計的財務結果。
A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, . A replay of the webcast will be archived on Avadel's website for 90 days following the event.
可以通過訪問公司網站的投資者關係部分來訪問該電話的音頻現場直播。會議結束後，Avadel的網站將對網絡廣播進行90天的存檔。
Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
參與者可以在此處註冊電話會議，並建議至少在加入會議前10分鐘進行註冊。
About Avadel Pharmaceuticals plc
關於Avadel Pharmaceuticals，plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel's commercial product, LUMRYZ, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit .
Avadel Pharmaceuticals plc（納斯達克：AVDL）是一家生物製藥公司，致力於通過改變藥物來改善生活。我們的做法包括爲解決患者在當前治療方案中面臨的挑戰開發創新解決方案。Avadel的商業產品LUMRYZ已被美國食品和藥物管理局（FDA）批准爲首個也是唯一一個在睡前服用的氧酸鹽，用於治療7歲及以上患有嗜睡症的患者的發作性肌無力或過度 daytime 嚴重睏倦。欲了解更多信息，請訪問。
Investor Contact:
投資者聯繫人：
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionaq.com
(212) 698-8696
奧斯汀·穆爾塔
精準AQ
Austin.Murtagh@precisionaq.com
(212) 698-8696
Media Contact:
媒體聯繫人：
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
萊斯利·斯坦利
真實化學
lestanley@realchemistry.com
(609) 273-3162
譯文內容由第三人軟體翻譯。
